{{Drugbox
| IUPAC_name = ''N''-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1''H''-indazole-3-carboxamide
| image = ADB-FUBINACA_structure.png

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_DE = Anlage II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Schedule I
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1445583-51-6
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 70969086
| ChemSpiderID      = 29763706
| UNII = 05235E1S2O
| smiles            = O=C(NC(C(N)=O)C(C)(C)C)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3
| StdInChI          = 1S/C21H23FN4O2/c1-21(2,3)18(19(23)27)24-20(28)17-15-6-4-5-7-16(15)26(25-17)12-13-8-10-14(22)11-9-13/h4-11,18H,12H2,1-3H3,(H2,23,27)(H,24,28)
| StdInChIKey       = ZSSGCSINPVBLQD-UHFFFAOYSA-N

<!--Chemical data-->
| C=21 | H=23 | F=1 | N=4 | O=2
| molecular_weight = 382.43 g/mol
}}

'''ADB-FUBINACA''' is a [[designer drug]] identified in [[synthetic cannabis]] blends in Japan in 2013.<ref>{{cite journal | first1=N. | last1=Uchiyama | url=https://link.springer.com/article/10.1007%2Fs11419-013-0182-9 | title=Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products | date=July 2013 | last2=Matsuda | first2=S. | last3=Kawamura | first3=M. | last4=Kikura-Hanajiri | first4=R. | last5=Goda | first5=Y. | journal=Forensic Toxicology | volume=31 | issue=2 | pages=223–240 | doi=10.1007/s11419-013-0182-9}}</ref> The (''S'') enantiomer of ADB-FUBINACA is claimed in [[Pfizer]] [[patent]] WO 2009/106982 and has been reported to be a potent [[agonist]] of the [[Cannabinoid receptor type 1|CB<sub>1</sub> receptor]] and [[Cannabinoid receptor type 2|CB<sub>2</sub> receptor]] with an [[EC50|EC<sub>50</sub>]] value of 1.2&nbsp;nM and 3.5&nbsp;nM respectively.<ref>{{cite journal | author1=Samuel D Banister | author10=Michelle Glass | author11=Mark Connor | author12=Iain S McGregor | author13=Michael Kassiou | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00112 | title=The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA | date=July 2015 | author2=Michael Moir | author3=Jordyn Stuart | author4=Richard C Kevin | author5=Katie E Wood | author6=Mitchell Longworth | author7=Shane M Wilkinson | author8=Corinne Beinat | author9=Alxendra S Buchanan | journal=ACS Chemical Neuroscience | volume=6 | issue=9 | pages=1546–1559 | doi=10.1021/acschemneuro.5b00112 | pmid=26134475}}</ref><ref>[http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009106982 Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982]</ref> ADB-FUBINACA features a carboxamide group at the 3-indazole position, like [[SDB-001]] and [[STS-135 (drug)|STS-135]]. ADB-FUBINACA appears to be the product of rational drug design, since it differs from [[AB-FUBINACA]] only by the replacement of the [[isopropyl group]] with a [[tert-butyl|''tert''-butyl group]].

An analogue of ADB-FUBINACA, [[ADSB-FUB-187]], containing a more functionalized carboxamide substituent was recently reported.

== Side effects ==

One death through coronary [[Thrombosis#Arterial thrombosis|arterial thrombosis]] has been linked to ADB-FUBINACA intoxication.<ref>{{cite journal | author1=Kevin G. Shanks | url=http://jat.oxfordjournals.org/content/early/2016/01/10/jat.bkv142.abstract | title=Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA | date=April 2016 | author2=William Clark | author3=George Behonick | journal=Journal of Analytical Toxicology | volume=40 | issue=3 | pages=236–239 | doi=10.1093/jat/bkv142 | pmid=26755539}}</ref>

== Legality==
In the United States, 5DB-FUBINACA is a [[Controlled_Substances_Act#Schedule_I_controlled_substances|Schedule I controlled substance]].<ref>{{cite web | url = https://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr1221.htm | title = Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I | publisher = [[Drug Enforcement Administration]]}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-AMB]]
* [[5F-APINACA]]
* [[AB-CHFUPYCA]]
* [[AB-PINACA]]
* [[ADB-CHMINACA]]
* [[ADB-PINACA]]
* [[ADBICA]]
* [[ADSB-FUB-187]]
* [[APINACA]]
* [[MDMB-CHMICA]]
* [[MDMB-FUBINACA]]
* [[PF-03550096]]
* [[PX-3]]
{{Div col end}}

==References==
<references/>

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Fluoroarenes]]
[[Category:Indazoles]]
[[Category:Indazolecarboxamides]]
[[Category:Tert-butyl compounds]]